Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RoosterBio, Senti Biosciences Partner on Cell Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

RoosterBio, Senti Biosciences Partner on Cell Therapy

Collaboration leverages cGMP clinical systems to accelerate gene modified cell therapy for solid tumors

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RoosterBio has entered a clinical supply and manufacturing collaboration agreement with gene circuit company Senti Biosciences to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and current Good Manufacturing Practices (cGMP)-compliant, hMSC-focused manufacturing capabilities.  
 
“Gene-modified cell therapies are one of the most important segments in our industry, and we are excited to help Senti Biosciences accelerate its technology into the clinic,” said Jon Rowley founder and chief product officer, RoosterBio. “Our collaboration reflects the importance of strategically positioned gene engineering platforms that are designed for rapid clinical translation. RoosterBio’s goal of radically simplifying hMSC product development, process development and clinical manufacturing are being leveraged to move the field of cell therapy forward.”
 
Philip Lee, chief operating officer and co-founder, Senti, said, “Gene circuits have the potential to lead the next wave of cell and gene therapies to address the high unmet need in difficult-to-treat cancers, such as ovarian cancer. We look forward to continuing our collaboration with RoosterBio to accelerate clinical development of our novel gene circuit MSC-based therapies to help bring those therapies to patients as efficiently and safely as possible.”
 
Senti will apply its novel gene circuit technology to hMSCs produced by RoosterBio’s breakthrough CliniControl hMSC manufacturing platform. In addition, Senti will employ RoosterBio for external development of hMSC supply and expansion, including bioreactor scale-up and industrialized large-scale manufacturing unit operations.
 
RoosterBio’s proprietary, clinically relevant product portfolio was introduced in 2017 under the CliniControl brand name with the promise to radically simplify multiple steps in therapeutic development. CliniControl is the first hMSC product to be commercialized as off-the-shelf, cGMP-compliant working cell bank and bioprocess media systems.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics